The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Structure, Function, and Therapeutic Use of IgM Antibodies
Open accessAbstract
Natural immunoglobulin M (IgM) antibodies are pentameric or hexameric macro-immunoglobulins and have been highly conserved during evolution. IgMs are initially expressed during B cell ontogeny and are the first antibodies secreted following exposure to foreign antigens. The IgM multimer has either 10 (pentamer) or 12 (hexamer) antigen binding domains consisting of paired µ heavy chains with four constant domains, each with a single variable domain, paired with a corresponding light chain. Although the antigen binding affinities of natural IgM antibodies are typically lower than IgG, their polyvalency allows for high avidity binding and efficient engagement of complement to induce complement-dependent cell lysis. The high avidity of IgM antibodies renders them particularly efficient at binding antigens present at low levels, and non-protein antigens, for example, carbohydrates or lipids present on microbial surfaces. Pentameric IgM antibodies also contain a joining (J) chain that stabilizes the pentameric structure and enables binding to several receptors. One such receptor, the polymeric immunoglobulin receptor (pIgR), is responsible for transcytosis from the vasculature to the mucosal surfaces of the lung and gastrointestinal tract. Several naturally occurring IgM antibodies have been explored as therapeutics in clinical trials, and a new class of molecules, engineered IgM antibodies with enhanced binding and/or additional functional properties are being evaluated in humans. Here, we review the considerable progress that has been made regarding the understanding of biology, structure, function, manufacturing, and therapeutic potential of IgM antibodies since their discovery more than 80 years ago.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
The double life of a B-1 cell: self-reactivity selects for protective effector functions
Baumgarth, N. (2011) · Nature Reviews Immunology · doi:10.1038/nri2901 · Cited by 969
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Kim, J. Y., Kim, Y.-G., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3758-5 · Cited by 801
Greenman, R. L. (1991) · JAMA · doi:10.1001/jama.266.8.1097 · Cited by 752
Shaw, P. X., Hörkkö, S., Chang, M.-K., Curtiss, L. K., Palinski, W., Silverman, G. J., & Witztum, J. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8472 · Cited by 676
Gonzalez-Quintela, A., Alende, R., Gude, F., Campos, J., Rey, J., Meijide, L. M., Fernandez-Merino, C., & Vidal, C. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03545.x · Cited by 630
Griffin, D. O., Holodick, N. E., & Rothstein, T. L. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101499 · Cited by 615
Role of natural and immune IgM antibodies in immune responses
Boes, M. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00025-6 · Cited by 602
Cited by
Sepsis—Pathophysiology and Therapeutic Concepts
Jarczak, D., Kluge, S., & Nierhaus, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.628302 · Cited by 453
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 267
CD5L is a canonical component of circulatory IgM
(2023) · doi:10.1073/pnas.2311265120 · Cited by 47
Metadata
- Authors
- Keyt, B. A., Baliga, R., Sinclair, A. M., Carroll, S. F., & Peterson, M. S.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2020-10-13
- Volume
- 9
- Issue
- 4
- Pages
- 53
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W3092796309
- Cited by
- 254
- References
- 120
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structure, Function, and Therapeutic Use of IgM Antibodies. https://app.cochat.ai/papers/10.3390/antib9040053
- The paper
- Keyt, B. A., Baliga, R., Sinclair, A. M., Carroll, S. F., & Peterson, M. S. (2020). Structure, Function, and Therapeutic Use of IgM Antibodies. Antibodies. https://doi.org/10.3390/antib9040053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.